SAN RAMON, Calif., January 25, 2021—To support the education of countless future eye care professionals, CooperVision has committed funding for the new eye care clinic at The Ohio State University College of Optometry. Contact lens services provided by the clinic include soft contact lens fittings for the correction of myopia, astigmatism, and presbyopia, as well as myopia management for children through CooperVision’s Brilliant FuturesTM Myopia Management Program featuring MiSight® 1 day.*
Opened last month, Ohio State’s Optometry Clinic and Health Sciences Faculty Office Building is a six-story facility with 56 exam rooms in which optometry students are able to see patients. The clinic offers primary vision care, contact lens fittings, dry eye treatment, vision therapy, and pediatric services. There is also an optical shop with more than 3,000 frames on display.
“With the continuous advancement of contact lens technologies, it is more important than ever for optometry students to receive thorough education specific to this area of optometry practice,” said Michele Andrews, OD, Vice President of Professional & Government Affairs, Americas, CooperVision. “The College’s investment in this state-of-the-art clinic will provide invaluable firsthand learning opportunities for these students while also providing top-quality care for its community. CooperVision is proud to be a part of it.”
College of Optometry Dean Dr. Karla Zadnik observed, ”Given my own early roots in the area of contact lenses and my career-long commitment to patient-oriented research in myopia, this significant gift from CooperVision delights me. Our students will learn about both fields in the best facility from the best people in the field.”
CooperVision’s support of Ohio State’s new clinic is the first of several expanded partnerships with optometry programs across the nation.
# # #
*Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters(spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.
Heather Kowalczyk, APR
McDougall Communications for CooperVision, Inc.
email@example.com or +1-585-434-2148